Skip to main content
SpringerLink
Log in

Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom

  • Chapter
Regionale Therapie maligner Tumoren

  • 1146 Accesses

Zusammenfassung

Das Pankreaskarzinom stellt nach wie vor eine Herausforderung in der Krebsbehandlung dar. Aufgrund der sehr spät eintretenden Symptome erreicht die 5-Jahres-Überlebensrate kaum 5%, und es sterben jedes Jahr etwa genauso viele Patienten am Pankreaskarzinom wie neu diagnostiziert werden. Dies spiegelt die schlechte Prognose dieses Tumors wider. Zum Zeitpunkt der Diagnose ist nur bei 10– 15% der Patienten das Tumorwachstum lokal noch so begrenzt, dass eine chirurgische Resektion möglich ist. Die systemische Chemotherapie ist bislang noch von sehr geringem Nutzen und geht meist mit einer nicht unwesentlichen Toxizität einher.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Burris HA 3rd, Moore MJ, Andersen J et al: Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413, 1997.

    PubMed  CAS  Google Scholar 

  2. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) with gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl (2005) 3(2):12.

    Google Scholar 

  3. Cunningham D, Chau I, Stocken D, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. J Clin Oncol 27:5513–5518, 2009.

    Article  PubMed  CAS  Google Scholar 

  4. Scheithauer W, Schull B, Ulrich-Pur H, et al: Biweekly highdose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: A randomized phase II trial: Ann Oncol 14: 97–104, 2003.

    Article  PubMed  CAS  Google Scholar 

  5. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212–2217, 2007.

    Article  PubMed  CAS  Google Scholar 

  6. Berlin JD, Catalano P, Thomas JP, et al: Phase III study of gemcitabine in combination with Fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20:3270–3275, 2002.

    Article  PubMed  CAS  Google Scholar 

  7. Heinemann V, Quietzsch D, Gieseler F, et al: A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma. Proc Ann Soc Clin Oncol 22:250, 2003.

    Google Scholar 

  8. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22:3776–3783, 2004.

    Article  Google Scholar 

  9. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in Combination with Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. J Clin Oncol 23:3509–3516, 2005.

    Article  PubMed  CAS  Google Scholar 

  10. Poplin E, Feng Y, Berlin J, et al: Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778–3785, 2009.

    Article  PubMed  CAS  Google Scholar 

  11. El-Rayes BF, Zalupski MM, Shields AF, et al: Phase II study gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer. J Clin Oncol 21: 2920–2925, 2003.

    Article  PubMed  CAS  Google Scholar 

  12. Alberts SR, Schroeder M, Erlichman C, et al: Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma. A North Central Cancer Treatment Group Phase II Trial. J Clin Oncol 22: 4944–4950, 2004.

    Article  PubMed  CAS  Google Scholar 

  13. Kulke Matthew H, Tempero Margaret A, Niedzwiecki Donna, et al: Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904. J Clin Oncol 27:5506–5512, 2009.

    Article  PubMed  CAS  Google Scholar 

  14. Ducreux M, Rougier P, Pignon JP, et al: A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191, 2002.

    Article  PubMed  CAS  Google Scholar 

  15. Colucci G, Giuliani F, Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 94:902–910, 2002.

    Article  PubMed  CAS  Google Scholar 

  16. Maisey N, Chau I, Cunningham D, et al: Multicenter randomized phase III trial of protracted venous infusion of 5-fluorouracil with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20:3130–3136, 2002.

    Article  PubMed  CAS  Google Scholar 

  17. Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24: 4441–4447, 2006.

    Article  PubMed  CAS  Google Scholar 

  18. Oettle H, Richards D, Ramanathan RK, et al: A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16:1639–1645, 2005.

    Article  PubMed  CAS  Google Scholar 

  19. Van Cutsem E, van de Velde H, Karasek P, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22:1430–1438, 2004.

    Article  PubMed  Google Scholar 

  20. Bramhall SR, Schulz J, Nemunaitis J, et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87:161–167, 2002.

    Article  PubMed  CAS  Google Scholar 

  21. Van Cutsem E, Vervenne W, Bennouna J, et al: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 27:2231–2237, 2009.

    Article  PubMed  Google Scholar 

  22. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (2007) 25(15):1960–1966.

    Article  PubMed  CAS  Google Scholar 

  23. Chua YJ, Zalcberg JR: Pancreatic Cancer – is the Wall Crumbling? Ann Oncol. 19(7):1224–1230, 2008.

    Article  PubMed  CAS  Google Scholar 

  24. Stephens FO: Why use regional chemotherapy? Principles and pharmacokinetics. Reg Cancer Treat (1988) 1:4–10.

    Google Scholar 

  25. Cantore M, Fiorentini G, Luppi G, et al: Randomised Trial of Gemcitabine Versus Flec Regimen Given Intra-Arterially for Patients with Unresectable Pancreatic Cancer. J. Exp. Clin. Cancer Res., 22, 4, 2003.

    Google Scholar 

  26. Miller DW, Fontain M, Kolar C, et al: The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 1996; 107: 301–306.

    Article  PubMed  CAS  Google Scholar 

  27. Verovski VN, Van den Berge DL, Delvaeye MM, et al: Lowlevel doxorubicin resistance in P-glycoprotein-negative human pancreatic tumor PSN1/ADR cells implicates a brefeldin A-sensitive mechanism of drug extrusion. Br J Cancer 1996; 73:596–602.

    Article  PubMed  CAS  Google Scholar 

  28. Kartner N, Riorden JR, Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 221: 1285–8, 1983.

    Article  PubMed  CAS  Google Scholar 

  29. Goldstein LJ, Galski H, Fojo A, et al: Expression of the multidrug resistance gene product P-glycoprotein in human cancer. J. Natl Cancer Inst. 81: 116, 1989.

    Article  PubMed  CAS  Google Scholar 

  30. Aigner KR, Müller H, Basserman R: Intra-arterial chemotherapy with MMC, CDDP and 5-FU for nonresectable pancreatic cancer – a phase II study. Reg Cancer Treat (1990) 3: 1–6.

    Google Scholar 

  31. Aigner KR, Gailhofer S: Celiac Axis Infusion and Microembolization for Advanced Stage III/IV Pancreatic Cancer – A Phase II Study on 265 Cases. Anticancer Research 25:4407–4412, 2005.

    PubMed  Google Scholar 

  32. Ishikawa O, Ohigashi H, Imaoka S, et al: Regional chemotherapy to prevent hepatic metastasis after resection of pancreatic cancer. Hepatogastroenterology 1997 Nov- Dec;44(18):1541–6.

    Google Scholar 

  33. Beger HG, Gansauge F, Büchler MW, et al: Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer: significant reduction in occurrence of liver metastasis. World J Surg 1999 Sep;23(9): 946–9.

    Google Scholar 

  34. Aigner KR, Gailhofer S, Kopp S: Regional Versus Systemic Chemotherapy for Advanced Pancreatic Cancer: A Randomized Study. Hepato-Gastroenterology 1998; 45: 1125–1129.

    PubMed  CAS  Google Scholar 

  35. Gillen S, Schuster T, Meyer Zum Buschenfelde C, Friess H, et al: Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS medicine 2010; 7:el 000267.

    Article  Google Scholar 

  36. Collins, J.M.: Pharmacologic rationale for regional drug delivery. J. clin. Oncol. 2: 498–504 (1984).

    PubMed  CAS  Google Scholar 

  37. Stephens FO, Harker GJS, Dickinson RTJ, Roberts BA (1979): Preoperative basal chemotherapy in the management of cancer of the stomach: a preliminary report. Aus NZ J Surg 49: 331.

    Article  CAS  Google Scholar 

  38. Stephens FO, Crea P, Harker GJS, Roberts BA, Hambly CK (1980): Intra-arterial chemotherapy as basal treatment in advanced and fungating primary breast cancer. Lancet 2: 435.

    Article  PubMed  CAS  Google Scholar 

  39. Stephens FO (1983) Clinical experience in the use of intraarterial infusion chemotherapy in the treatment of cancers in the head and neck, the extremities, the breast and the stomach. In: Schwemmle K, Aigner KR (eds) Vascular perfusion in cancer therapy. Springer, Berlin Heidelberg New York, (Recent results in cancer research, vol 86, p 122).

    Google Scholar 

  40. Frei, E., III; Canellos, G.P.: Dose: A critical factor in cancer chemotherapy. Am. J. Med. 69: 585 – 594 (1980).

    Article  PubMed  Google Scholar 

  41. Klopp CT, Alford TC, Bateman J, Berry GN, Winship T (1950) Fractionated intra-arterial cancer chemotherapy with methyl bis-amine hydrochloride; a preliminary report. Ann Surg 132: 811–832.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abteilung für Onkologische Chirurgie, Medias Klinikum GmbH & Co. KG, Krankenhausstraße 14a, 84489, Burghausen, Deutschland

    Prof. Dr. Karl R. Aigner & Dr. Sabine Gailhofer

  2. Department of Surgical Oncology (Emeritus) Sheba Medical Center Ramat-Gan, Tel-Aviv University, Medical School, Tel-Aviv, Israel

    Prof. Dr. Gur Ben-Ari (Head)

Authors
  1. Prof. Dr. Karl R. Aigner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. Sabine Gailhofer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. Gur Ben-Ari
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medias Klinikum Burghausen, Burghausen

    Karl Reinhard Aigner

  2. University of Sydney, Sydney, Australia

    Frederick O. Stephens

  3. Universitätsklinikum Frankfurt, Frankfurt

    Thomas J. Vogl

  4. Universitätsklinikum Gießen, Gießen

    Winfried Padberg

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Aigner, K.R., Gailhofer, S., Ben-Ari, G. (2013). Systemische und regionale Chemotherapie beim fortgeschrittenen und metastasierten Pankreaskarzinom. In: Aigner, K.R., Stephens, F.O., Vogl, T.J., Padberg, W. (eds) Regionale Therapie maligner Tumoren. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35014-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-35014-6_17

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-35013-9

  • Online ISBN: 978-3-642-35014-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation